Two thirds of the vaccines and medicines in our pipeline address infectious diseases (including HIV). Infectious diseases are responsible for one in six deaths globally. There is a huge need for innovation to tackle chronic infections, seasonal infections, common childhood diseases, rare but devastating conditions such as meningitis, and a range of bacterial infections made more challenging by antimicrobial resistance; as well as diseases which largely impact lower-income countries like malaria and tuberculosis.

We are also committed to addressing neglected tropical diseases (NTDs), which disproportionately affect some of the world’s most vulnerable populations. We are providing access to medicines, supporting disease surveillance and control programs, and advocating for increased awareness and resources to combat NTDs.

Our combined expertise in vaccines and medicines means we can focus on both the prevention and treatment of infectious diseases, resulting in significant public health benefits, reduced deaths and increased productivity.